Select Your Region
Global
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
- Cancer
- Solid Tumors
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:
Recruiting
This study runs in
Cities
- Ankara
- Asvestochori
- Athina
- bad-saarow
- Bangalore
- Bangkok
- banglore
- Beirut
- Beograd
- Berlin
- Besançon
- Blackpool
- bogota--d-c-
- Bogotá
- Bratislavský kraj
- Brest
- Bristol
- Buenos Aires
- Caen
- Cairo Governorate
- Calgary
- Cali
- Cebu City
- Chennai
- Chihuahua
- Ciudad de México
- Clermont-Ferrand
- Dijon
- Dubai
- Dublin
- eastbourne
- Edirne
- Exeter
- faliro
- Gloucester
- Golnik
- Graz
- Guildford
- Halle (Saale)
- Hamburg
- Hannover
- Hanoi
- Heilbronn
- Ho Chi Minh City
- Hyderabad
- Istanbul
- Izmir
- Jaén
- Jerusalem
- Johannesburg
- Kaohisung
- Las Condes
- Levallois-Perret
- Lille
- Lisboa
- Ljubljana
- London
- Lyon
- Marseille
- Medellín
- Mumbai
- Málaga
- Mönchengladbach
- New Castle Upon Tyne
- New Delhi
- Northwood
- Ottawa
- Palma De Mallorca
- Pamplona
- Paris
- Porto
- Porto Alegre
- Pretoria
- Puebla
- Pécs
- Quezon City
- Quimper
- Rennes
- Reutlingen
- Rio de Janeiro
- Riyadh
- Saida
- Saint-Étienne
- Santiago
- sar-yer--stanbul
- seyhan-adana
- Somerset
- Sremska Kamenica
- St Etienne
- Stuttgart
- sutton-in-ashfield
- São Paulo
- Taipei City
- Tallinn
- Taoyuan County
- Tartu
- Tel Aviv
- thane
- Thessaloniki
- Torquay
- Toulon
- VILLEJUIF Cedex
- Warszawa
- Wesel
- Zaragoza
Trial Identifier:
NCT04529122 MX39897
Study Summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
Hoffmann-La Roche
Sponsor
N/A
Phase
NCT04529122, MX39897
Trial Identifier
Solid Tumours
Condition
Official Title
A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Participant is an adult (according to the age of majority as defined by local regulations)
- Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
- Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
- Informed consent has been obtained from the participant or legally authorized representative, as per local regulations
Exclusion Criteria
- Participant has a prior or current diagnosis of haematological malignancy
For the latest version of this information please go to www.forpatients.roche.com